Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University of Chicago
Massachusetts General Hospital
Servier
Groupe Francophone des Myelodysplasies
Northwestern University
University of Chicago
Yale University